Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

FDA accepts Vitrase NDA for filing

Oct. 10, 2003

No Comments

Novartis presents new IOP-lowering agents in recent patent

Oct. 10, 2003

No Comments

Improved vision observed in phase I/II trial of squalamine in wet AMD

Oct. 9, 2003

No Comments

Integrin antagonists useful for angiogenesis-related ocular diseases

Sep. 30, 2003

No Comments

FDA accepts for filing diquafosol NDA for dry eye

Sep. 15, 2003

No Comments

EntreMed grants Oxford BioMedica gene rights for ophthalmic applications

Sep. 12, 2003

No Comments

Good efficacy and safety profile described for ranibizumab in AMD

Sep. 3, 2003

No Comments

Intravitreous hyaluronidase effective in reducing vitreous hemorrhage density

Sep. 3, 2003

No Comments

VEGF Trap prevents blinding blood vessel growth in mice

Aug. 28, 2003

No Comments

Improved vision in extension phase of Lucentis wet AMD study

Aug. 27, 2003

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Ocular
RSS

FDA accepts Vitrase NDA for filing

Novartis presents new IOP-lowering agents in recent patent

Improved vision observed in phase I/II trial of squalamine in wet AMD

Integrin antagonists useful for angiogenesis-related ocular diseases

FDA accepts for filing diquafosol NDA for dry eye

EntreMed grants Oxford BioMedica gene rights for ophthalmic applications

Good efficacy and safety profile described for ranibizumab in AMD

Intravitreous hyaluronidase effective in reducing vitreous hemorrhage density

VEGF Trap prevents blinding blood vessel growth in mice

Improved vision in extension phase of Lucentis wet AMD study

Today's news in brief

Today's news in brief

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

Proteomics study explores how protein changes influence disease

Abbvie and Simcere enter a $1B T-cell engager deal

Ocular RSS

Ocular
RSS